MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.jaad.2024.04.045

Медицинская библиотека · Journal of the American Academy of Dermatology · 2024

A randomized, double-blind, phase III study assessing clinical similarity of SB17 (proposed ustekinumab biosimilar) to reference ustekinumab in subjects with moderate-to-severe plaque psoriasis.

Feldman Steven R, Narbutt Joanna, Girolomoni Giampiero, Brzezicki Jan, Reznichenko Nataliya, Zegadło-Mylik Maria Agnieszka, Pulka Grazyna, Dmowska-Stecewicz Magdalena, Kłujszo Elżbieta, Rekalov Dmytro, Rajzer Lidia, Lee Jiyoon, Lee Minkyung, Rho Young Hee

СтатьяРандомизированное исследованиеКлиническое исследование III фазыМногоцентровое исследованиеСравнительное исследованиеПеревод пока не подготовлен

Аннотация

BACKGROUND

Ustekinumab (UST) is a safe and effective treatment for moderate-to-severe psoriasis.

OBJECTIVES

To compare efficacy, safety, pharmacokinetics (PK), and immunogenicity of the proposed UST biosimilar SB17 with reference UST in subjects with moderate-to-severe plaque psoriasis.

METHODS

In this randomized double-blind study, subjects were randomized to receive 45 mg of SB17 or UST subcutaneously at week 0, 4, and every 12 weeks. The primary endpoint was the percent change from baseline in Psoriasis Area and Severity Index at week 12 with an equivalence margin of [-15%, 15%]. Other secondary efficacy, safety, PK, and immunogenicity endpoints were measured through week 28.

RESULTS

Two hundred forty-nine subjects were randomized to SB17, 254 to UST. Adjusted difference of Psoriasis Area and Severity Index change from baseline at week 12 of -0.6% (95% confidence interval; -3.780, 2.579) was within the equivalence margin. Physician's Global Assessment and Dermatology Life Quality Index were also comparable. Overall treatment-emergent adverse events were comparable (SB17: 48.2%, UST: 48.8%). The overall incidence of antidrug antibodies up to Week 28 was 13.3% with SB17 and 39.4% with UST.

LIMITATIONS: Data were only through week 28.

CONCLUSION

SB17 was clinically biosimilar to UST up to week 28.

Для цитирования: Feldman Steven R, Narbutt Joanna, Girolomoni Giampiero, Brzezicki Jan, Reznichenko Nataliya, Zegadło-Mylik Maria Agnieszka, Pulka Grazyna, Dmowska-Stecewicz Magdalena, Kłujszo Elżbieta, Rekalov Dmytro, Rajzer Lidia, Lee Jiyoon, Lee Minkyung, Rho Young Hee. A randomized, double-blind, phase III study assessing clinical similarity of SB17 (proposed ustekinumab biosimilar) to reference ustekinumab in subjects with moderate-to-severe plaque psoriasis.. Journal of the American Academy of Dermatology. 2024. DOI: 10.1016/j.jaad.2024.04.045.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.